{"doi":"10.1037/abn0000965","title":"Prevalence, incidence, impairment, course, and diagnostic progression and transition of eating disorders, overweight, and obesity in a large prospective study of high-risk young women.","abstract":"= 19.7 years) who completed diagnostic interviews over a 3-year period. The baseline prevalence of any eating disorder was 13.3% and 25.4% showed onset (incidence) over 3-year follow-up. Baseline prevalence of overweight and obesity were 17.2% and 11.9%, respectively, with respective 3-year incidence rates of 18.3% and 6.8%. The average duration of eating disorders ranged from 2.2 to 5.0 months. Episode duration for overweight and obesity were 14.9 and 20.0 months, respectively. Most eating disorders (82%-96%) showed remission within 1 year; recurrence rates varied from 12% (atypical anorexia nervosa [AN]) to 44% (subthreshold bulimia nervosa). Three-year remission rates for overweight (53%) and obesity (34%) were lower, as was recurrence (15% and 9%, respectively). All eating disorders were characterized by a mixture of binge eating and compensatory weight control behaviors. Functional impairment was elevated for half the examined eating disorders and obesity. Diagnostic progression varied from 3% of those with atypical AN progressing to AN to 29% of those with subthreshold binge eating disorder progressing to binge eating disorder. Regarding diagnostic crossover, the most frequent pattern was shifting from a threshold to a subthreshold eating disorder, followed by shifting from a binge-related eating disorder to overweight. Results extend knowledge of the natural history of eating disorders and provide novel evidence of the relation between eating disorders and overweight/obesity. (PsycInfo Database Record (c) 2025 APA, all rights reserved).","journal":"Journal of Psychopathology and Clinical Science","year":2024,"id":455025,"datarank":0.37020404138011004,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0582878101281346,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0582878101281346,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":6,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.6852,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT00663754","NCT01126918","NCT01949649"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":390403,"name":"C. Desjardins","orcid":"0000-0002-8234-9665","position":1,"is_corresponding":false},{"id":712903,"name":"Heather Shaw","orcid":"0000-0003-3210-4819","position":2,"is_corresponding":false},{"id":630438,"name":"Sarah Siegel","orcid":"0000-0001-8249-2632","position":3,"is_corresponding":false},{"id":1279313,"name":"Kristen Gee","orcid":null,"position":4,"is_corresponding":false},{"id":545827,"name":"Paul Rohde","orcid":"0000-0002-6869-6513","position":5,"is_corresponding":false},{"id":472678,"name":"Eric Stice","orcid":"0000-0002-9632-1540","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:03:17.458329Z","pmid":"39509183","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}